High triglycerides quietly build up in your blood, raising the risk of heart attack, stroke, and other serious problems. For many people, even when LDL cholesterol is under control with statins, triglycerides remain high and continue to fuel hidden danger.
You eat better, you exercise, you take your medications, yet your blood results still show risk.
That is where Vascepa can help. With its purified EPA formula, it lowers triglycerides and also helps stabilize plaques, reduce inflammation, and cut cardiovascular events.
| 🔑 Key takeaways ➤ Vascepa is a purified form of EPA that lowers triglycerides without raising LDL cholesterol, unlike many fish oil products. ➤ It helps reduce triglycerides by cutting liver fat production, improving lipoprotein quality, and stabilizing artery plaques. ➤ Clinical trials show Vascepa lowers the risk of heart attack, stroke, and other cardiovascular events, even in people already on statins. ➤ Some studies raised doubts, but most evidence supports Vascepa’s heart-protective benefits beyond just lowering triglycerides. ➤ Side effects include a slightly higher risk of atrial fibrillation and bleeding, so doctors monitor patients closely. ➤ Generic versions now make Vascepa more affordable, widening access for people who need added protection against heart disease. |
What is Vascepa and what does it do?
Vascepa, also called icosapent ethyl (IPE), is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA).
According to a study, it was the first fish oil–based product that the U.S. Food and Drug Administration (FDA) approved specifically to reduce the risk of atherosclerotic cardiovascular disease in adults. Unlike common fish oil supplements, which often contain both EPA and DHA, Vascepa contains only EPA in an ethyl ester form. This makes it unique because it avoids the LDL cholesterol-raising effect sometimes linked with DHA.
The FDA initially approved Vascepa in 2012 for patients with very high triglycerides. The drug’s journey began with the MARINE and ANCHOR trials, which showed it could significantly lower triglycerides in patients with severe hypertriglyceridemia and in those with moderately high levels.
Later, after the large REDUCE-IT trial, the FDA extended Vascepa’s label in 2019 to include patients with triglycerides ≥150 mg/dL who also had established cardiovascular disease or diabetes with risk factors.
Vascepa became widely used as an add-on to statins because it addresses “residual risk” that statins alone cannot fully cover. They highlighted that while statins lower LDL cholesterol, many patients still face cardiovascular risk due to high triglycerides and inflammation. Vascepa works in that space, offering benefits beyond traditional cholesterol drugs.
So, what does Vascepa really do?
At its core, it lowers triglycerides and helps protect against heart attacks, strokes, and other cardiovascular events.
But as later sections will show, its benefits extend beyond just lowering triglycerides.
How does it lower Triglyceride levels?
IPE lowers triglycerides through several biological pathways.
According to a 2023 study, omega-3 fatty acids reduce the production of very low-density lipoproteins (VLDL) in the liver and shift LDL particles from small, dense forms to larger, more stable ones. This reduces circulating triglycerides and helps improve the lipid profile.
The ANCHOR trial, as mentioned above, showed Vascepa effectively reduced triglycerides in patients with levels ≥200 to <500 mg/dL, even when they were already on statins. One of Vascepa’s key advantages is that it lowers triglycerides without raising LDL cholesterol, unlike some other omega-3 mixtures that include DHA.
One systematic review further described how Vascepa not only reduces triglycerides but also influences inflammation and oxidative stress, both of which contribute to atherosclerosis. The drug incorporates into cell membranes, making plaques more stable and less likely to rupture.
In the EVAPORATE trial, the researchers provided imaging evidence to support this mechanism. They studied patients on statins with triglycerides around 259 mg/dL. After 18 months, those treated with Vascepa had a 17% reduction in low-attenuation plaque volume, while the placebo group’s plaque volume more than doubled.
This showed that Vascepa directly impacts plaque characteristics in addition to lowering triglycerides.
Taken together, these studies suggest that Vascepa lowers triglycerides by cutting down on liver fat production, stabilizing plaques, reducing inflammation, and improving lipoprotein quality. This multi-pronged effect helps explain why its benefits go beyond just changing triglyceride numbers on a lab test.
Does it improve cardiovascular outcomes beyond lowering TG?
Yes.
The same study above was the most influential. It enrolled 8,179 statin-treated patients with triglycerides between 135 and 499 mg/dL and LDL cholesterol between 41 and 100 mg/dL. Patients received either Vascepa 4 g/day or placebo and were followed for a median of 4.9 years.
The results were striking. The primary endpoint, a combination of cardiovascular death, heart attack, stroke, revascularization, or unstable angina, occurred in 17.2% of patients on Vascepa compared to 22.0% on placebo. The key secondary endpoint of cardiovascular death, heart attack, or stroke was also significantly lower. Even cardiovascular death alone was reduced.
But not every trial agreed. The STRENGTH trial, with 13,078 patients, tested an omega-3 carboxylic acid formulation (EPA + DHA) versus corn oil. It was stopped early for futility. Both groups had identical rates of major adverse cardiovascular events (12%). This raised questions about whether DHA might blunt EPA’s benefits or whether the mineral oil placebo in REDUCE-IT exaggerated Vascepa’s effects.
Despite the controversy, evidence strongly supports cardiovascular protection with Vascepa. Earlier data from JELIS, a Japanese trial with 18,645 patients, also showed a 19% reduction in cardiovascular events with EPA added to statins.
Thus, while STRENGTH created doubts, most clinical and imaging data point toward Vascepa improving outcomes beyond triglyceride lowering.
Safety Concerns and limitations
While Vascepa has many benefits, it also comes with some safety concerns and practical challenges.
Risk of atrial fibrillation and bleeding
One of the main safety issues relates to heart rhythm problems and bleeding.
The REDUCE-IT trial, as mentioned above, showed that atrial fibrillation or flutter occurred more often in the Vascepa group (3.1%) compared with placebo (2.1%), and this difference was statistically significant. Serious bleeding events were also slightly more common with Vascepa, although this did not reach statistical significance.
This shows that while the overall risk is low, physicians should be careful when prescribing Vascepa to patients with a history of arrhythmias or those already on blood thinners.
Controversy over trial comparisons
Safety discussions are also linked to debates about trial designs. The REDUCE-IT’s use of a mineral oil placebo raised questions. Mineral oil slightly increased LDL cholesterol, apolipoprotein B, and C-reactive protein in the placebo group, which might have made Vascepa’s benefits look larger.
By contrast, the STRENGTH trial, which used corn oil, showed no benefit for an omega-3 mix of EPA and DHA.
Regulators like the FDA and EMA concluded that the biomarker effects of mineral oil likely explained only a small part of the difference, but the debate has not completely gone away.
Accessibility and cost issues
Another limitation relates to access. Invalidation of Amarin’s core patents opened the door for generic competitors. While this improves affordability, it also complicates the drug’s market presence and the financial incentives for further research. High cost was a barrier when only brand Vascepa was available, and the arrival of generics has partially solved this problem.
Favorable profile compared to other Omega-3s
On the positive side, Vascepa has a cleaner lipid profile than other omega-3 formulations because it contains purified EPA. Unlike DHA-containing products, it does not raise LDL cholesterol.
This makes it safer for patients who are already dealing with high cardiovascular risk and elevated LDL.
Wrap up
Vascepa offers a proven way to lower triglycerides while also protecting the heart. It works through many pathways, such as cutting liver fat production, improving the quality of lipoproteins, calming inflammation, and making artery plaques more stable. These effects explain why people taking Vascepa face fewer heart attacks, strokes, and cardiovascular deaths.
Although some studies raised debate, the strongest evidence shows real benefit. Like any medicine, it carries some risks, such as bleeding or irregular heartbeat, but overall the safety profile is favorable. With generics now available, Vascepa is more accessible and continues to play a vital role in heart health.
FAQs on Vascepa for triglycerides
Who should not take VASCEPA?
Don’t take VASCEPA if you are allergic to icosapent ethyl, its ingredients, or if you’ve had allergic reactions to fish or shellfish.
What are the most common side effects?
The most common side effects include joint or muscle pain, swelling in hands or feet, constipation, gout, and irregular heartbeat.
Can VASCEPA cause serious side effects?
Yes. Serious side effects may include irregular heart rhythms, bleeding, or severe allergic reactions. Call your doctor right away if you notice symptoms.
Can children take VASCEPA?
It is not known if VASCEPA is safe or effective for children. It is only prescribed for adults.
Can VASCEPA be taken with other medicines?
Yes, but tell your doctor about all medicines you take, especially blood thinners, as VASCEPA may increase bleeding risk.
How is VASCEPA taken?
VASCEPA is usually taken as capsules, along with a low-fat, low-cholesterol diet. Your doctor will tell you the right dose for you.
Sources
- Huston, J., Schaffner, H., Cox, A., Sperry, A., Mcgee, S., Lor, P., Langley, L., Skrable, B., Ashchi, M., Bisharat, M., Gore, A., Jones, T., Sutton, D., Sheikh-Ali, M., Berner, J., & Goldfaden, R. (2023). A critical review of icosapent ethyl in cardiovascular risk reduction. American Journal of Cardiovascular Drugs, 1–14. Advance online publication. https://doi.org/10.1007/s40256-023-00583-8
- Curfman, G., & Shehada, E. (2021). Icosapent ethyl: Scientific and legal controversies. Open Heart, 8(1), e001616. https://doi.org/10.1136/openhrt-2021-001616
- Gupta, A., & Alkhalil, M. (2023). The emerging role of icosapent ethyl in patients with cardiovascular disease: Mechanistic insights and future applications. Journal of Clinical Medicine, 12(11), 3758. https://doi.org/10.3390/jcm12113758
- Sutariya, B., Montenegro, D. M., Chukwu, M., Ehsan, P., Aburumman, R. N., Muthanna, S. I., Menon, S. R., Vithani, V., & Penumetcha, S. S. (2022). Emphasis on icosapent ethyl for cardiovascular risk reduction: A systematic review. Cureus, 14(12), e32346. https://doi.org/10.7759/cureus.32346
- Budoff, M. J., Bhatt, D. L., Kinninger, A., Lakshmanan, S., Muhlestein, J. B., Le, V. T., May, H. T., Shaikh, K., Shekar, C., Roy, S. K., … & EVAPORATE Study Group. (2020). Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: Final results of the EVAPORATE trial. European Heart Journal, 41(40), 3925–3932. https://doi.org/10.1093/eurheartj/ehaa652
- Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., & Japan EPA Lipid Intervention Study (JELIS) Investigators. (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. The Lancet, 369(9567), 1090–1098. https://doi.org/10.1016/S0140-6736(07)60527-3